SMAWF - Renalytix AI Looks For U.S. Public Capital In IPO Filing
Quick Take
Renalytix AI (RNLX) has filed to raise $86.25 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement.
The firm is developing an AI-enhanced diagnostics system for chronic kidney disease.
RNLX is still in development stage for its first system.
I’ll provide a final opinion when we learn more IPO details.
Company & Technology
Cardiff, UK-based Renalytix was founded to create an artificial intelligence-based diagnostics system for kidney and potentially other chronic disease conditions.
Management is headed by co-founder and Chief Executive Officer Mr.